Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hubei Tongji Benda Ebei Pharmaceutical Co, a subsidiary of Amersin Life Sciences Corporation, has entered into a sales contract with Zhangjiang Pharmacy Co to supply 1.5 million doses of Ribavirin in injection form.
Subscribe to our email newsletter
Zhangjiang Pharmacy is a pharmaceutical distribution company specializing in South East Asia markets including Thailand, Vietnam, and Burma. Many of its customers, especially those from Vietnam and Thailand, are building inventories of antiviral products following recently confirmed human cases of bird flu (H5N1).
“The market demand for our Ribavirin product is strong and continues to grow,” said Reid Li, chairman & CEO of Amersin Life Sciences. “We look forward to working with pharmaceutical distributors, including Zhangjiang, to expand our reach domestically and abroad.”
Ribavirin is a systemic antiviral, marketed by Schering-Plough as Rebetol and by Roche as Copegus in the US. It is used to treat severe viral pneumonia in infants and young children and, in combination with interferon, to treat hepatitis C.
In January, Hubei revealed plans to increase production of Ribavirin injections by 30% in response to market demand, following recent avian flu outbreaks in Asia.